Objective: To ascertain the genetic and functional basis of complex autosomal recessive cerebellar ataxia (ARCA) presented by 2 siblings of a consanguineous family characterized by motor neuropathy, cerebellar atrophy, spastic paraparesis, intellectual disability, and slow ocular saccades.
undiagnosed, 2, 3, 5 implying that a large number of causative genes-usually the most rare and challenging to identify-still need to be uncovered.
Here, we report the identification and characterization of a novel ARCA causative mutation in CHP1 (calcineurin homologous protein-1, NM_007236.4:c.52_54del: p.Lys19del). CHP1 serves as an essential cofactor of NHE1 (sodium/hydrogen exchanger 1), 6 ,7 a major regulator of intracellular ions and pH homeostasis. 8 Biallelic splice mutation of mouse Chp1 leads to reduced NHE1 membrane targeting and degeneration of Purkinje cells, ultimately causing ataxia. 6 Similarly, mouse Nhe1 (encoded by Slc9a1) knockout (KO) causes Purkinje cell loss, severe locomotor ataxia, and epilepsy, 9 ,10 while homozygous loss-of-function SLC9A1 mutations in humans cause cerebellar ataxia and sensorineural hearing loss. 11 Therefore, we hypothesized that a mutation in CHP1, as a crucial regulator of NHE1, 6, 7 could impair expression and targeting of the exchanger, resembling the pathogenesis in mice and humans. Taking advantage of the zebrafish model system for modeling ARCAs, [12] [13] [14] we generated a chp1-deficient zebrafish, which not only resembled the clinical features of the affected siblings but also corroborates the pathogenicity of the CHP1 hypomorphic Lys19del mutation in vitro and in vivo. Whole-exome sequencing and whole-genome linkage analysis. Whole-exome sequencing (WES) of individuals 1, 2, 6, and 8 of family AAR-087 was performed on the Illumina HiSeq 2000 as paired-end 100bp reads after library preparation with the SureSelect Human All Exon 50 Mb V4 kit (Agilent Technologies. Santa Clara, California). ARCA and NeurOmics cohort WES and bioinformatic processing details are given in supplemental data. Whole-genome linkage analysis was performed using Illumina LINKAGE_12 microarrays (6090 single nucleotide polymorphism markers). Genotypes were determined by BeadStudio (Illumina, San Diego, CA) and analyzed with MERLIN 1.0. 15 Expression vector generation and site-directed mutagenesis.
Full-length human CHP1 complementary DNA (cDNA) (NCBI: 11261) was cloned into 2 expression vectors: pcDNA3.1/ CT-V5His-TOPO and pcDNA3.1/CT-green fluorescent protein (GFP)-TOPO following the manufacturer's instructions (Life Technologies, Darmstadt, Germany). K19del mutation was introduced by site-directed mutagenesis (see primers, table e-1 at links.lww.com/NXG/A29), following QuikChange kit instructions (Agilent Technologies, Santa Clara, CA). Clones were verified by Sanger sequencing.
Cell culture and transfection. HEK293T (human embryonic kidney), HeLa (human cervical carcinoma), PC12 (murine pheochromocytoma), and N2A (murine neuroblastoma) cells were grown, maintained, and differentiated following standard protocols. Cells were transfected with plasmid DNAs, including control empty vectors, using Lipofectamine2000 (Life Technologies) and harvested after 24, 48, or 72 hours for RNA and protein isolation.
Semiquantitative reverse transcription PCR. RNA was extracted using the RNeasy kit (Qiagen, Hilden, Germany), and concentrations were determined using the RiboGreen method (Life Technologies). Three hundred nanograms of RNA were reverse transcribed to cDNA with the Quantitect Reverse Transcription Kit (Qiagen). PCR was performed with low cycle number (N 5 24) and as multiplex with the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) (see primers, Zebrafish experiments. Experiments for caudal primary motor neuron (CaP-MN) analysis were performed with the transgenic line tg(mnx1-GFP)ml2TG (synonym TL/EK-hb9-GFP 17 ). Cerebellar analyses were performed in the wild-type (WT) TL/EK line. Control and chp1 Morpholinos (MO) (against translational start codon, table e-1, links.lww.com/NXG/A29) were designed and purchased from GeneTools, LLC (Philomath, OR). WT and mutant human CHP1 cDNAs were introduced into a pCS21 vector for in vitro transcription of capped messenger RNAs (mRNAs), performed as previously described. 16 Zebrafish protein lysates for WB were prepared following the protocol described in reference 18 with modifications, explained in e-Methods. Embryo injections and CaP-MN immunostaining were performed as previously described. 16 For cerebellar immunostainings, ;72-hpf zebrafish larvae were fixed overnight in Dent solution and processed as described in reference 12. Antibodies used are listed in table e-2, links.lww.com/NXG/A29. Neurologic readouts quantification, movement analysis, and imaging procedures are given in supplemental data.
Microscopy. Images were acquired using a Zeiss AxioImager M2 microscope equipped with ApoTome2 system to mimic confocality (Zeiss, Jena, Germany). Zebrafish CaP-MN and cerebellum images were acquired as Z-stacks and processed using ZEN software. Colocalization analyses were performed with ZEN. Representative images were processed using ImageJ. All experiments were blinded.
Protein modeling. Protein structures of free CHP1 (2CT9) and NHE1-bound CHP1 (2E30) were acquired from RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). Cartoon representations were generated using PyMOL 1.5.0.4.
Statistics. Statistical analyses were performed using GraphPad Prism 6. Two-tailed Student t tests, x 2 , and Fisher exact statistics tests were performed. Levels of statistical significance are given in GraphPad format (*p # 0.05, **p # 0.01, ***p # 0.001, and ****p # 0.0001). Specific tests, sample size, data representation, and p values are indicated in figure legends.
RESULTS Identification of a 3-bp deletion in CHP1 causes autosomal recessive spastic ataxia. Two of 6 siblings of a consanguineous Moroccan family (figure 1A) developed autosomal recessive spastic ataxia with onset during the first decade of life. They show gait instability with moderate cerebellar atrophy ( figure 1B) in the family (table e-4, links.lww.com/NXG/A29, and figure e-1, A and B, links.lww.com/NXG/A30). Further filtering based on alternate allele homozygosity and weak mutation effect prediction excluded 5 variants (table e-4, links.lww.com/NXG/A29). Of these, a biallelic 3-bp deletion in CHP1 (NM_007236.4:c.52_ 54del:p.Lys19del), hereafter defined as K19del, was validated by Sanger sequencing ( figure 1C ) and further selected as a top disease candidate since (1) it is located in the largest nonexcluded region on chromosome 15, where the maximum LOD score is reached, (2) it is absent from all public databases, (3) the mutation affects an amino acid highly conserved across species (figure 1D), (4) a point mutation reported in mouse Chp1, causing aberrant splicing and reduced full-length transcripts, leads to degeneration of Purkinje cells and ataxia, 6 (5) CHP1 assists posttranscriptional glycosylation and membrane localization of NHE1; a major Na 1 /H 1 exchanger listed in the ataxia-ome, 19 (6) KO of mouse Nhe1 also cause ataxia, 10 and (7) mutations in NHE1 cause ataxia-deafness Lichtenstein-Knorr syndrome (LKS). 11 Neither focused screening for CHP1 variants in 2 large cohorts, namely ARCA (N 5 319) and NeurOmics (individuals with various neuromuscular diseases N 5 657) nor GeneMatcher 20 interrogation revealed any additional variant in CHP1, fulfilling our pathogenic selection criteria (table e-5, links.lww. com/NXG/A29).
Endocrine dysfunction is CHP1 independent. The syndromic presentation of ataxia with hypergonadotropic hypogonadism was first described in 1908 21, 22 ; nonetheless, the genetic basis of this combination, except for few successful studies, 12, 23 remains elusive. The female proband of this study presented with ovarian failure; however, neither Chp1 vacillator nor Nhe1-depleted female mice were reported as infertile. Our analysis of uteri from vacillator mice showed neither uterus nor ovarian impairments (data not shown). We speculated that a CHP1-independent mutation might account for this defect, further clarifying the CHP1 family pathogenic landscape. WES revealed a homozygous variant (c.859C.T, p.G258E) in Basonuclin-1 (BNC1), which encodes a protein expressed only in reproductive germ cells with an essential function in oogenesis and spermatogenesis 24, 25 (table e-4, links.lww.com/NXG/A29). Bnc-1 null mice are sex-differentially affected, with females presenting complete infertility and subfertile males exhibiting smaller testes and reduced sperm motility. 24, 25 Furthermore, a pathogenic copy number variant including the BNC1 gene was recently detected in a retrospective study of spontaneous premature ovarian failure susceptibility.
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CHP1-K19del mutation alters protein solubility. To investigate the effect of CHP1-K19del, we examined the expression of CHP1-WT and CHP1-K19del-V5-tagged proteins in transiently transfected HEK293T cells by WB. Time-course analysis revealed reduced CHP1-K19del-V5 expression, whereas CHP1-WT-V5 exhibited higher levels over 72 hours of overexpression (OE) (figure 2A and figure e-2A). Semiquantitative reverse transcription PCR (RT-PCR) showed no differences between WT and mutant CHP1 transcripts (figure 2B and figure e-2B, links.lww.com/NXG/A30), thus excluding a transcriptional impairment.
Next, we assessed the distribution of CHP1-WT and mutant in soluble and insoluble fractions. Compared with CHP1-WT-V5 levels, CHP1-K19del-V5 was ;62% reduced in the soluble fraction and increased by ;68% in the insoluble fraction, respectively ( figure 2C ). Similar results were seen in N2A cells (figure e-2C, links.lww.com/NXG/A30). Together, these observations hint toward defects in protein localization, solubility, or stability of the CHP1 mutant form which, alone or in combination, might explain the reduced levels of soluble protein.
Mutant CHP1 is prone to aggregation. Given the clear effect of the K19del mutation on CHP1 expression, we investigated the cellular localization of WT and mutant CHP1-GFP-tagged proteins in N2A (figure 3A), PC12, and HeLa cells (figure e-3, A and B, links.lww.com/NXG/A30) via fluorescence microscopy.
CHP1-WT-GFP staining displayed a uniform distribution throughout the cells, including neurite-like structures in N2A and PC12 cells ( figure 3A and figure e-3A, links.lww.com/NXG/A30), whereas CHP1-K19del-GFP expression led to massive protein aggregates, which on detailed observation revealed 2 distinct patterns: small puncta-like structures and large amorphous accumulations with a very strong fluorescent signal. These aggregates were observed in cell body and neurite-like projections ( figure 3A) . Quantification of total accumulation/aggregation events in N2A cells showed that ;50% of CHP1-K19del-GFP cells presented aggregates compared with ;20% in CHP1-WT-GFP cells. Large aggregations were detected almost exclusively in CHP1-K19del-GFP cells (;22% vs ;4% in the WT; p , 0.001) ( figure 3A) . Similar accumulation patterns were observed in PC12 and HeLa cells (figure e-3, A and B, links.lww.com/NXG/A30).
To further characterize these abnormal protein aggregates, CHP1-WT-and K19del-GFP-expressing cells were stained for protein homeostasis markers such as ubiquitin and P62 [27] [28] [29] ( figure 3 , B and C). Larger aggregates displayed positive colocalization and extensive accumulation of both markers, indicating that these structures are recognized by neuronal protein quality control systems, thus explaining CHP1-K19del-reduced expression. Altogether, these results strongly indicate that K19del causes an increased proneness of CHP1 to aggregation, potentially attributable to misfolding and/or structural protein defects.
The K19del mutation alters CHP1 association into functional complexes and impairs NHE1 membrane targeting. To conclusively confirm that the K19del mutation leads to formation of higher molecular size CHP1 species, we performed SEC. Elution profiles of CHP1-WT-V5 and K19del-V5 proteins were determined by V5-immunoblotting. CHP1-WT-V5 eluted in 2 regions, representing the monomeric CHP1 form (;25 KDa) 30, 31 and the high-molecularweight (HMW) complexes (;1 MDa). By contrast, the CHP1-K19del-V5 elution profile shifted not only away from the monomeric range toward higher fractions but also appeared in HMW fractions in which CHP1-WT is absent ( figure 4A and e-4A ). NHE1 elution also showed marked differences. A unique band was detected Figure 2 The K19del mutation affects the expression and solubility of CHP1 (A) Western blot (WB) from HEK293T lysates transiently expressing CHP1-WT-V5, CHP1-K19del-V5, or empty V5-vector (control) collected 24, 48, and 72 hours after transfection. Protein lysates were probed with antibodies against V5 to detect CHP1-WT and mutant proteins, and GAPDH as loading control. Expression of CHP1-K19del-V5 is almost undetectable after 72 hours. The graph represents quantification of CHP1 relative expression over different time points. Bars show the mean 6 SEM. (B) Determination of CHP1-WT-V5 and K19del-V5 transcripts by semiquantitative RT-PCR. The graph represents quantification of CHP1-V5 transcripts normalized to HPRT expression. Bars show the mean 6 SEM. Negligible differences were observed between WT and CHP1-K19del transcripts. (C) Subcellular fractionation of protein lysates from HEK293T transiently overexpressing CHP1-WT-V5 or CHP1-K19del-V5 48 hours after transfection. Lysates were separated into soluble (cytoplasmic) and insoluble (cytoskeletal) fractions by differential lysis and centrifugation. Representative WB from total lysates and fractions were probed with V5 antibodies to detect CHP1-WT and mutant proteins. HSP90 and Vimentin were used as enrichment markers for soluble and insoluble fractions, respectively. Graphs represent quantification of relative expression of CHP1 in the soluble and insoluble fractions. Bars show the mean 6 SEM from 3 independent blots. "*" denotes statistical significance (p # 0.05 two-tailed Student t test) between CHP1-WT and CHP1-K19del expression. GAPDH 5 glyceraldehyde 3-phosphate dehydrogenase; HPRT 5 hypoxanthine-guanine phosphoribosyltransferase; WT 5 wild type.
in CHP1-WT HMW fractions, while 3 bands were observed for CHP1-K19del. Immunoblotting of glyceraldehyde 3-phosphate dehydrogenase, an interacting partner of CHP1, 32 did not show differences between CHP1-WT and mutant elution profiles (figure e-4A, links.lww.com/NXG/A30). These results demonstrate that additional higher molecular complexes of CHP1-K19del-V5 are formed, which result from the unspecific aggregation proneness of mutant CHP1.
Characterization studies of the CHP1-NHE1 complex demonstrate that this calcium-dependent interaction exclusively involves 8 specific residues of the aJ helix of the C-terminal region of CHP1. 7, 30 These findings excluded the possibility of a direct implication of K19 in the interaction between both proteins. Examination of the crystal structure of CHP1 30 revealed that K19 is localized on the CHP1 first N-terminal Aa helix (figure 4B). Of interest, comparison of this structure with an NMR-generated CHP1-NHE1 segment complex structure 33 indicated that CHP1-Aa undergoes large conformational changes on NHE1 binding, forming a clamp fixating NHE1-C-terminal segment (figure 4B). Although the structure-function relationship of this feature is poorly understood, this structural analysis suggests that K19del could interfere with a fully functional CHP1-NHE1 complex formation impairing NHE1 targeting to the membrane or compromising the function of this complex.
Since membrane localization of CHP1 is dependent of NHE1, 6 but also membrane expression and maturation of NHE1 is reliant on CHP1, 34 we investigated the effect of CHP1-K19del on NHE1 membrane targeting. Thereby, membrane fractions from HEK293T cells expressing CHP1-WT-and K19del-V5-tagged proteins were analyzed by WB. In line with reduced cytoplasmic levels, CHP1-K19del membrane expression was also markedly diminished ( figure 4C ). It is important that marked NHE1 reduction in membrane fractions was observed on OE of mutant CHP1 (figure 4C), implying that CHP1-K19del interferes with proper NHE1 membrane targeting. Similar results were seen in N2A cells (figure e-4B, links.lww.com/NXG/A30). K19del mutation alters CHP1 association into functional complexes, impairs NHE1 membrane targeting, and potentially compromises protein conformational changes (A) Size-exclusion chromatography of total protein lysates from HEK293T cells expressing CHP1-WT-V5 and CHP1-K19del-V5. 42 protein fractions, 21 in the range of high molecular weight (HMW) and 21 in low molecular weight (LMW) were analyzed by Western blot (WB). Blots were probed with V5 antibodies to detect CHP1 WT and mutant proteins. Marked elution differences between WT and mutant CHP1 in both HMW and LMW complexes (fractions 7-25) are visible. CHP1-K19del-V5 elution in LMW fractions shifted to higher MW (29) (30) , away from the most abundant monomeric range (32) (33) (34) .
(B) Cartoon representation of the crystal structure of Rattus norvegicus free CHP1 (PDB code 2CT9) and Homo sapiens NMR complex structure NHE1-bound CHP1 (PDB code 2E30). CHP1 is depicted in gray, the NHE1 segment in magenta, and Ca 21 ions in green. The CHP1 Aa helix (residues 1 to 23) is depicted in blue and the K19 residue is shown in orange sticks. Note the open conformation of the CHP1 Aa helix in the free CHP1 structure and its closed-to-NHE1 hydrophobic pocket in the CHP1-bound structure. (C) Subcellular fractionation of protein lysates from HEK293T transiently overexpressing CHP1-WT-V5 and CHP1-K19del-V5 proteins. Fractions were separated into soluble (cytoplasmic) and membrane fractions by differential lysis and centrifugation. Representative WB of total lysates and fractions were probed with V5 antibodies to detect CHP1-WT and mutant proteins and NHE1. HSP90 and EGFR were used as enrichment markers for soluble and membrane fractions, respectively. Graphs represent quantification of relative expression of CHP1 and NHE1 in the membrane fraction. Bars show the mean 6 SEM (error bars) from 3 independent blots. "*" denotes statistical significance (p # 0.05 Student t test). EGFR 5 Epidermal Growth Factor Receptor; WT 5 wild type. Figure 5 Chp1 downregulation in zebrafish leads to CaP-MN, cerebellar, and movement defects rescued with WT, but not mutant CHP1 mRNA mutation in vivo, we used MO to inhibit chp1 translation in zebrafish. Different MO concentrations were injected to select a dosage with little effect on overall morphology and development, but quantifiable neurologic readout (figure e-5, A-D, links.lww.com/NXG/ A30). MO efficacy was confirmed by WB (figure e-5E, links.lww.com/NXG/A30).
Chp1 deficiency resulted in CaP-MN defects, namely axonal truncations and increased terminal branching. In detail, ;23% of the analyzed CaPMNs exhibited defects in axonal projection and ;35% showed increased terminal branching ( figure 5, A-C) . Furthermore, Chp1 reduction led to severe cerebellar hypoplasia in ;70% of the morphants. Trochlear decussation became visible on severe cerebellar reduction, and reduced size of the optic tectum was also observed but not included for quantification analyses (figure 5, E and F). Negligible CaP-MN impairments and no cerebellar defects were observed in control groups (figure e-5, B-D, links. lww.com/NXG/A30). Since individuals carrying CHP1 mutation exhibit spastic paraparesis, gait instability, and ataxia (table e-3, links.lww.com/NXG/A29), we additionally examined chp1 morphants movement in detail. Chp1 deficiency led to increased spontaneous contractions ( figure 5D and video e-1, links.lww.com/ NXG/A31) and to abnormal spastic-like trunk movement unaccompanied of locomotion (video e-2, links. lww.com/NXG/A32).
To corroborate chp1-MO phenotype specificity and confirm CHP1-K19del pathogenicity, rescue experiments were performed using WT and mutant CHP1-mRNAs. Protein OE was confirmed by WB (figure e-5F, links.lww.com/NXG/A30), and neither CaP-MN nor cerebellar defects were observed on CHP1-mRNAs OE (figure e-5, B-D, links.lww. com/NXG/A30). Coinjection of chp1 MO and CHP1-WT mRNA, but not CHP1-K19del mRNA, ameliorated all neurologic and movement defects associated with Chp1 deficiency (p # 0.05). Thus, CHP1-WT mRNA improved axonal truncations, terminal branching, and cerebellar hypoplasia by ;13%-20% and 25%, respectively, compared with chp1 MO alone (figure 5, A-C, E and F). Spontaneous contractions were partially restored to uninjected larvae levels ( figure 5D ). Rescue experiments did not fully reach control levels probably because of the limited expression of synthetic mRNAs. 35 Together, the neurologic and movement defects observed in chp1 morphants validate CHP1 reduction as the underlying cause of MN defects and ratify cerebellar hypoplasia as the central pathogenic feature underpinning CHP1 pathogenesis.
DISCUSSION Following a combination of exome and linkage analysis in a consanguineous family, we identified a 3-bp deletion in a highly conserved domain of CHP1 as a novel cause of ARCA. Neither focused CHP1 screening in 2 large cohorts with ARCA and NMD nor interrogating GeneMatcher 20 unraveled a second mutation, emphasizing the scarcity of CHP1 variants. This is further underpinned by the reduced tolerability for missense mutation found in control population (Exome Aggregation Consortium z-score: 2.64) and the high degree of conservation among CHP1 orthologs (99% amino acid identity in mouse and 92% in zebrafish).
Here, we demonstrated that CHP1-K19del severely affects protein expression and localization, thereby impairing NHE1 membrane expression, and consequently its function. 36 Therefore, CHP1 mutation causes ataxia, most likely, in an NHE1-dependent manner (figure e-6, A and B, links.lww.com/NXG/ A30), resembling the mechanism of cerebellar degeneration described for Chp1 vacillator 6 and Nhe1 KO mice. 9 Albeit aggregation is inherent to misfolded proteins in neurodegenerative disease, 29 the aggregation proneness described for CHP1-K19del should be considered as a readout of abnormal protein folding rather than a disease mechanism itself.
The affected siblings of this study present with cerebellar atrophy and motor neuropathy, which were recapitulated in zebrafish. chp1 morphants exhibited severe cerebellar hypoplasia and CaP-MN alterations, thus demonstrating that MNs are also compromised on CHP1 downregulation. Moreover, Chp1 reduction in zebrafish resulted in increased spontaneous contractions and spastic-like trunk movements, supporting that CHP1 deficiency underlies the spastic phenotype in humans. Although the common denominator between Chp1 and Nhe1 mouse models is Purkinje cell degeneration, other central nervous areas such as the hippocampus and hypothalamus are also sensitive to NHE1 depletion. 37, 38 We speculate that abundant NHE1 expression in MN 39 and MN precursors 40 might regulate the proclivity of this population to CHP1 misbalance. In contrast to the CHP1-deficient associated phenotype, NHE1 deficiency was presumptively associated with hearing loss, despite that neither Nhe1 nor Chp1 models presented deafness. More strikingly, depletion of mouse Nhe1 results in ataxia and epilepsy, while patients with LKS do not present with episodic seizures. 6, 9 This phenotypic variability strongly suggests that differential NHE1 dosages finely tune different pathogenic outcomes. Notably, CHP1-K19del reduces but not abolishes CHP1 expression, thereby NHE1 membrane targeting is reduced, but not fully compromised. We hypothesize, in conformity with others, 11 that reduced NHE1 certainly leads to ataxia, but remaining levels are sufficient to protect patients with CHP1 mutations from epilepsy or deafness as in patients with LKS. Moreover, tissue-specific expression of other CHP or NHE proteins could modulate phenotypic compensations, further explaining the incomplete phenotypic translation from mouse to humans and the variability among human phenotypes.
AUTHOR CONTRIBUTIONS
Designing the study, drafting the manuscript, data interpretation, and study supervision: N.M. 
ACKNOWLEDGMENT
The authors thank all participating family members, the IGenSeq facility, and the DNA and Cell Bank of the Institut du Cerveau et de la Moelle épinière. They also thank Markus Storbeck for support in protocols and experimental details; Isabelle Le Ber and Andrea Delle Vedove for advice in medical details; and Monia B Hammer for genotype analysis. M.C. was the recipient of a fellowship from the Fond National de la Recherche Scientifique (aspirant FNRS).
STUDY FUNDING

